Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc.ARCT · Entity 5523 | Director | June 05, 2026 | June 15, 2026 |
| Arcturus Therapeutics Ltd.ARCT · Entity 160417 | Director | January 01, 2019 | January 02, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcturus Therapeutics Holdings Inc.
Report date June 05, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2036-06-05 | Direct | 15,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 15,000 · Balance 15,000 F1: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer.
Arcturus Therapeutics Ltd.
Report date January 01, 2019 · Filed January 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2019-01-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 10,000 F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. F2: Vesting monthly over a two year period from August 24, 2018. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. F3: Vesting monthly over a one year period from August 24, 2018. |
| STOCK OPTION (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2028-08-23 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-01-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019.
F2: Vesting monthly over a two year period from August 24, 2018.
F3: Vesting monthly over a one year period from August 24, 2018.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 15, 2026 21:01 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001193805-26-000827 · e665582_4-barlow.xml · derivative · entry 1 BARLOW JAMES F · CIK 0001190637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2036-06-05 F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2026 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| June 09, 2025 Filed Jun 12, 2025 00:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $12.54 | $0.00 |
DisclosureSEC source: 0001193805-25-000873 · e664619_4-barlow.xml · derivative · entry 1 BARLOW JAMES F · CIK 0001190637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-06-09 F1 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $31.00 | $0.00 |
DisclosureSEC source: 0001193805-24-000825 · e663726_4-barlow.xml · derivative · entry 3 BARLOW JAMES F · CIK 0001190637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-06-14 F3 · security: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F3 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | Exercise / conversionDeferred Stock Units · Derivative | 3,131 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193805-24-000825 · e663726_4-barlow.xml · derivative · entry 2 BARLOW JAMES F · CIK 0001190637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,131 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. F1 · derivative.exercise_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. F1 · derivative.expiration_date: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | Exercise / conversionCommon Stock | 3,131 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-24-000825 · e663726_4-barlow.xml · nonDerivative · entry 1 BARLOW JAMES F · CIK 0001190637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. F1 · price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock, was granted on August 1, 2023 as a portion of the Reporting Person's 2023 annual grant, and vested at the Issuer's 2024 annual meeting of stockholders, which occurred on June 14, 2024. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:10 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantDeferred Stock Units · Derivative | 3,131 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-23-001070 · e618808_4-barlow.xml · derivative · entry 2 BARLOW JAMES F · CIK 0001190637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,131 Underlying: Common Stock · 3,131 shares Expires not disclosed F2 · derivative.exercise_price: Each deferred stock unit is economically equivalent to one share of the Issuer's common stock. F3 · derivative.exercise_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. F3 · derivative.expiration_date: Shares underlying the deferred stock units shall vest at the Issuer's 2024 annual meeting of stockholders. The shares underlying the deferred stock units will be issued on (or as soon as reasonably practicable following) the earlier of the Reporting Person's separation from service or a change in ownership of the Issuer or a substantial portion of its assets or a change in effective control of the Issuer within the meaning of regulations issued under Section 409A of the Internal Revenue Code. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:10 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock option (right to buy) · Derivative | 11,869 | $0.00 Strike: $34.92 | $0.00 |
DisclosureSEC source: 0001193805-23-001070 · e618808_4-barlow.xml · derivative · entry 1 BARLOW JAMES F · CIK 0001190637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,869 Underlying: Common Stock · 11,869 shares Expires 2033-08-01 F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant; provided however, that the remaining unvested balance will vest and become fully exercisable at the Issuer's 2024 annual meeting of stockholders. This represents a portion of the 2023 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 23:15 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $16.02 | $0.00 |
DisclosureSEC source: 0001193805-22-001021 · e621782_4-barlow.xml · derivative · entry 1 BARLOW JAMES F · CIK 0001190637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:31 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $35.09 | $0.00 |
DisclosureSEC source: 0001193805-21-000926 · e620746_4-barlow.xml · derivative · entry 1 BARLOW JAMES F · CIK 0001190637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-18 F1 · derivative.exercise_date: Shares underlying the option vest monthly over a one year period from the date of grant. This grant represents the annual grant to members of the Board of Directors. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:00 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $40.70 | $0.00 |
DisclosureSEC source: 0001193805-20-000743 · e619722_4-barlow.xml · derivative · entry 1 BARLOW JAMES F · CIK 0001190637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-21 F1 · derivative.exercise_date: Shares underlying the options vest monthly over a one year period from the date of grant. Read SEC document |
| October 25, 2019 Filed Oct 30, 2019 00:44 UTC | Arcturus Therapeutics Holdings Inc. ARCT · Entity 5523 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $10.23 | $0.00 |
DisclosureSEC source: 0000899243-19-026165 · doc4.xml · derivative · entry 1 BARLOW JAMES F · CIK 0001190637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-10-24 F1 · derivative.exercise_date: Shares underlying the options vest monthly over a one year period from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.